CSTL Castle Biosciences

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures. Castle was ranked 30th among 358 participating U.S. companies with 500-999 employees.

"Winning a fourth Top Workplaces USA Award is a testament to our exceptional Castle team and people-first culture," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We are committed to fostering an environment where employees feel valued, supported and empowered to drive innovation, and this recognition reflects their passion and dedication to making a meaningful impact on patient care."

More than 42,000 organizations were invited to participate in the Top Workplaces USA survey. Winners of the Top Workplaces USA list were chosen solely on employee feedback gathered through a third-party administered by Energage. Results were calculated by comparing the survey’s research-based statements, including 15 culture drivers that are indicative of high performance against industry benchmarks. Castle’s survey participation rate of 95% and employee engagement score of 85% were both above the benchmark averages of 56% and 74%, respectively, for other similar healthcare companies participating in the Top Workplaces USA program.

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That's something to be proud of. In today's market, leaders must ensure they’re allowing employees to have a voice and be heard. That's paramount. Top Workplaces do this, and it pays dividends.”

The comprehensive list of 2025 Top Workplaces USA can be found on and .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit  and connect with us on , ,  and . 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to worktogether.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 19 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or .

Investor Contact:

Camilla Zuckero

Media Contact:

Allison Marshall

Source: Castle Biosciences Inc.



EN
07/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Abi...

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its TissueCy...

 PRESS RELEASE

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperfo...

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announ...

 PRESS RELEASE

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients...

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage I-III cut...

 PRESS RELEASE

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma...

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and uveal melanoma (CM and UM, respectively) via poster presentations at the American Association for Cancer Research® (AACR) Annual Meeting 2025, being held April 25-30 in Chicago. "At Castle ...

 PRESS RELEASE

Castle Biosciences to Release First Quarter 2025 Financial Results and...

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch